Skip to main content
Fig. 3 | Journal of Neuroinflammation

Fig. 3

From: Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis

Fig. 3

Chronic phase glibenclamide reduces the inflammatory burden in EAE. White matter of lumbar spinal cord sections from non-EAE control (CTR), untreated EAE mouse (EAE), and EAE mouse treated with glibenclamide starting on pid-24 (EAE + G), examined at pid-40, stained with H&E or immunolabeled for CD45 (leukocyte), CD20 (B cells), or CD3 (T cells), as indicated; original magnification, × 200 (H&E) or × 400 (all immunolabelings); bar graphs: percent of quadrants with inflammatory cells on H&E; quantification of CD45+, CD20+, and CD3+ cells in white matter; 5 mice/group; ## P < 0.01 with respect to non-EAE control (CTR); **P < 0.01 with respect to untreated EAE; scale bars 100 μm

Back to article page